Atossa Therapeutics (NASDAQ:ATOS) shares are trading lower on Thursday.

The company announced it has contracted with Avance Clinical to conduct a clinical study for its AT-301 Nasal Spray for the company's second coronavirus therapeutics development program.

Atossa Therapeutics is a clinical-stage pharmaceutical company operating in the US. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer and other breast conditions. The clinical-Stage Programs of the company includes delivery of therapeutics through microcathe

Atossa Therapeutics shares were trading down 0.51% at $3.94 on Thursday. The stock has a 52-week high of $4.69 and a 52-week low of 76 cents.